SMi Group is thrilled to present the 3rd annual Allergies conference taking place on 6 - 7 July 2016 in London, UK. Aimed at an audience of senior scientists and allergy specialists involved in immunology and drug research, Allergies 2016 will provide the perfect platform to discuss pioneering clinical developments and the next generation of allergy therapeutics.
Created with a top panel of industry thought leaders, this year's event will look to capture expert insight by honing in on new pathways with novel vaccines and adjuvants, immunoassays for molecular diagnostic’s, paediatric allergies, personalised treatment, allergen specific immunotherapies, plus more.
Through strategic direction and regulatory guidance, the programme will look to strengthen knowledge in topics such as biomarker validation, and arm attendees with the key requirements and tools for successful trials and study outcomes.
SPEAKERS INCLUDE:
Carl Dolman, Immunoglobulins and Allergen Study, Director, NIBSC, MHRA
Anne Marie Salapatek, President and Chief Scientific Officer, Inflamax Research
Jean Cuine, Global Head of Non-Clinical and Pharmaceutical Development, Stallergenes Greer
Dirk-Jan Opstelten, RandD Director, HAL Allergy
Thierry Batard, Senior Dir. Innovation and Technological Platforms, Stallergenes Greer
Tim Higenbottam, RandD Director, Allergy Therapeutics
Karen Knipping, Senior Scientist, Danone Nutricia Research
Sophie Nutten, Group Leader of the Allergy Group, Nestle Research Centre
Kimihiro Okubo, Dept of Otorhinolaryngology, Nippon Medical School
REASONS TO ATTEND:
Learn about sublingual immunotherapy for cedar pollinosis and mite
Hear the latest updates on regulation and clinical trials for paediatric immunotherapy
Obtain an overview of the development of allergen-specific immunotherapy for allergic rhinitis and food allergy
Discover the nutritional approaches for primary prevention of allergic disease
Earlybird rates available online
Created with a top panel of industry thought leaders, this year's event will look to capture expert insight by honing in on new pathways with novel vaccines and adjuvants, immunoassays for molecular diagnostic’s, paediatric allergies, personalised treatment, allergen specific immunotherapies, plus more.
Through strategic direction and regulatory guidance, the programme will look to strengthen knowledge in topics such as biomarker validation, and arm attendees with the key requirements and tools for successful trials and study outcomes.
SPEAKERS INCLUDE:
Carl Dolman, Immunoglobulins and Allergen Study, Director, NIBSC, MHRA
Anne Marie Salapatek, President and Chief Scientific Officer, Inflamax Research
Jean Cuine, Global Head of Non-Clinical and Pharmaceutical Development, Stallergenes Greer
Dirk-Jan Opstelten, RandD Director, HAL Allergy
Thierry Batard, Senior Dir. Innovation and Technological Platforms, Stallergenes Greer
Tim Higenbottam, RandD Director, Allergy Therapeutics
Karen Knipping, Senior Scientist, Danone Nutricia Research
Sophie Nutten, Group Leader of the Allergy Group, Nestle Research Centre
Kimihiro Okubo, Dept of Otorhinolaryngology, Nippon Medical School
REASONS TO ATTEND:
Learn about sublingual immunotherapy for cedar pollinosis and mite
Hear the latest updates on regulation and clinical trials for paediatric immunotherapy
Obtain an overview of the development of allergen-specific immunotherapy for allergic rhinitis and food allergy
Discover the nutritional approaches for primary prevention of allergic disease
Earlybird rates available online
